Navigation Links
Invitrogen Launches i-Path -- A Unique Systems Biology Platform at BIO 2005

this nuclear transfer. Of these, 11 showed the formation of one pronucleus. In normal fertilisation the formation of male and female pronuclei is an important stage just before the maternal and paternal chromosomes start to pair up in preparation for the first cell division. In the case of these oocytes they had undergone a pseudo-fertilisation because the pronuclei were derived from whole foreign nuclei, each one with a complete set of homologous [matching] chromosomes, instead of from sperm and eggs which carry only one set of chromosomes each."

Five oocytes divided to the two-cell stage, and of these, three continued to divide to the six- to ten-cell stage. One embryo continued to develop to the compacted stage, when the individual cells started to flatten and increase their contact with one another.

Mr Heindryckx said: "To our knowledge, this is the first report describing the development of cloned human embryos using in vitro matured oocytes and non-autologous transfer via a conventional method of nuclear transfer.

"Our final goal is to use human therapeutic cloning for infertility treatment by creating artificial eggs and sperm for patients who are infertile because of absence or premature loss of eggs or sperm. We would do this by isolating embryonic stem cell lines from cloned early embryos and driving these embryonic stem cells to develop into eggs and sperm in the laboratory."

However, Mr Heindryckx warned that there was a long way to go and many problems to overcome before he and his colleagues could reach their goal.

"None of these early embryos developed to the blastocyst stage, and failure to do so could reveal some problems in gene activation, especially in cloned embryos. So, first we have to understand how to get cloned blastocysts of good quality from in vitro matured oocytes. This will be difficult because it is well known that embryonic development is compromised when in vitro matured oocytes are used, and
'"/>

Source:Invitrogen


Page: 1 2 3

Related biology news :

1. Kinovate Life Sciences Launches Nittophase?High Performance Solid Support For Oligonucleatide Synthesis
2. Affymetrix Launches New Globin-Reduction Kits and Protocol Developed with PreAnalytiX
3. IMF Launches World’s First DNA Database for Myeloma Patients
4. Breast Cancer May Be Uniquely Sensitive To Inhibitors Of PI3K Pathway
5. Unique library of plant genes germinates, takes root at UNC
6. Uniquely human component of language found in gregarious birds
7. Unique equine cataract surgery offered on routine basis
8. Unique dual target specificity of kinase inhibitor key for success against cancer
9. Unique soybean lines hold promise for producing allergy-free soybeans
10. Unique gene regulation gives chilly bugs survival advantage at bottom of the world
11. Unique tomatoes tops in disease-fighting antioxidants

Post Your Comments:
(Date:12/1/2009)...RNewswire/ -- iQor, a global provider of business ...n the 2009 InfoWorld 100 Awards Top 100 IT proje...eQ21. This was the first submission for iQor. ,...tigious list of companies," said Vikas Kapoor, pre...forming the way we do business, allowing us to wor...
(Date:12/1/2009)...ersity-led international research team has develop...xt generation of solar cells. , Scientists at Mo...from the universities of Wollongong and Ulm in Ger...lls with a three-fold increase in energy conversio...dem dye-sensitised solar cells. , Lead research...
(Date:12/1/2009)...sed video of individual breast tissue cells reveal... a protein that cycles between two major compartme...re complete view of the internal signals that caus... in cancer and are targets of drug development. ,...rowth factors, travels back and forth between the ...
Breaking Biology News(10 mins):iQor Named to InfoWorld 100 List of Top IT Projects of 2009 2Innovation puts next-generation solar cells on the horizon 2ERK's got rhythm: Protein that controls cell growth found to cycle in and out of cell nucleus 2ERK's got rhythm: Protein that controls cell growth found to cycle in and out of cell nucleus 3ERK's got rhythm: Protein that controls cell growth found to cycle in and out of cell nucleus 4American Academy of Dermatology to Hold Summer Scientific Meeting in Boston 53038 1Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 1Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 2Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 3Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 4Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 5Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 6Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 7Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 8Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 9Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 10Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 11Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 12Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 13Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 14Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 15Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 16Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 17Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 18Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 19Sanofi aventis Announces Second Quarter 2009 Results 13244 1Sanofi aventis Announces Second Quarter 2009 Results 13244 2Sanofi aventis Announces Second Quarter 2009 Results 13244 3Sanofi aventis Announces Second Quarter 2009 Results 13244 4Sanofi aventis Announces Second Quarter 2009 Results 13244 5Sanofi aventis Announces Second Quarter 2009 Results 13244 6Sanofi aventis Announces Second Quarter 2009 Results 13244 7Sanofi aventis Announces Second Quarter 2009 Results 13244 8Sanofi aventis Announces Second Quarter 2009 Results 13244 9Sanofi aventis Announces Second Quarter 2009 Results 13244 10Sanofi aventis Announces Second Quarter 2009 Results 13244 11Sanofi aventis Announces Second Quarter 2009 Results 13244 12Sanofi aventis Announces Second Quarter 2009 Results 13244 13Sanofi aventis Announces Second Quarter 2009 Results 13244 14Sanofi aventis Announces Second Quarter 2009 Results 13244 15Sanofi aventis Announces Second Quarter 2009 Results 13244 16Sanofi aventis Announces Second Quarter 2009 Results 13244 17Sanofi aventis Announces Second Quarter 2009 Results 13244 18Sanofi aventis Announces Second Quarter 2009 Results 13244 19Sanofi aventis Announces Second Quarter 2009 Results 13244 20Sanofi aventis Announces Second Quarter 2009 Results 13244 21Sanofi aventis Announces Second Quarter 2009 Results 13244 22Sanofi aventis Announces Second Quarter 2009 Results 13244 23Sanofi aventis Announces Second Quarter 2009 Results 13244 24Sanofi aventis Announces Second Quarter 2009 Results 13244 25Sanofi aventis Announces Second Quarter 2009 Results 13244 26Sanofi aventis Announces Second Quarter 2009 Results 13244 27
... Next month in Boston, the AVS 55th International ... across the spectrum of science and engineering de...nterfaces, in plasmas, and in other controlled env...logies. , AVS is an interdisciplinary nonprofit ...iversities, government agencies, and industrial la...
...active oxygen species (ROS) occur as a by-product ... by damaging proteins, nucleotides and lipids. Or...ms to mitigate the effects of ROS, and the oxidati...hat physiological performance declines with age du...ogressively limited anti-oxidant capacity. Hence,...
...bal Carbon Budget was launched simultaneously by G...rance at the Paris Observatory, and in the USA at ... Pep Canadell. , The Global Carbon Project posted...dget, a key to understanding the balance of carbon...n induced climate change. Despite the increasing i...
Other Biology News:Save-the-date: Major nanotech, energy, and biomed meeting 2Save-the-date: Major nanotech, energy, and biomed meeting 3Save-the-date: Major nanotech, energy, and biomed meeting 4Researchers discover that growing up too fast may mean dying young in honey bees 2Researchers discover that growing up too fast may mean dying young in honey bees 3Growth in the global carbon budget 2
(Date:12/1/2009)... Congruent Software agree...including project accounting clients) to Synergy B... Seattle, WA (PRWEB) Decemb... today it has acquired the Microsoft Dynamics SL p...ness technology provider. The move was necessary d...
(Date:12/1/2009)..., , CRANBURY, N.J., Dec. 1 /PRNewswire-Fir... PTN ) today announced that the U.S. Patent and Tr...0, titled "Cyclic Natriuretic Peptide Constructs."...f cyclic compounds that bind to natriuretic peptid...lead heart failure drug candidate. ,, "Our natr...
(Date:12/1/2009)..., , SAN DIEGO, Dec. 1 /PRNewswire... Board: AEMD) announced today that it will present...3, 2009 at 2:00 p.m. (PST) at the Luxe Hotel in Lo...es A. Joyce, will present a corporate overview and...progress for its lead product, the Hemopurifier...
(Date:12/1/2009)..., , HUNTINGTON BEACH, California ... a world leader in molecular cancer diagnostics, a...t B Medicare administrator, has established,coding...maPrint is Agendia,s,FDA-cleared breast cancer rec...since 2008. , Patients across the United ...
Breaking Biology Technology:Synergy Business Solutions Acquires the Microsoft Dynamics SL Practice of Congruent Software, Inc. 2Synergy Business Solutions Acquires the Microsoft Dynamics SL Practice of Congruent Software, Inc. 3Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate 2Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate 3Aethlon Medical to Present at LD MICRO Conference on December 3, 2009 2Medicare Administrator Establishes Reimbursement Coding Policy for Agendia's Breast Cancer Recurrence Test MammaPrint(R) 2
...d Wave Technologies , compensation in a patent law... legal fees. Stratagene is proceeding with its app... the judge found that Stratagene willfully infring...ethods, and awarded Madison-based Third Wave $5.3 ...Invader line of products. Stratagene was given an ...
...ur taxes supporting? , ,This question becomes very...urced to other countries by the thousands and many...ats important. Educators better get with the progr...bility to learn and compete. , ,The latest decisio...now includes Bank One) to shift 7,000 financial jo...
...omote your business than by writing good, helpful ...d content attracts good traffic. , ,On an average ...Internet, according to the PEW Internet and Ameri... activities include getting news and finding infor...e got good content on your site, that can be found...
Other Biology Technology:With flawed schools exposed, real-world experience is needed 2With flawed schools exposed, real-world experience is needed 3With flawed schools exposed, real-world experience is needed 4The write stuff: marketing with articles 2The write stuff: marketing with articles 3The write stuff: marketing with articles 4
Polystyrene Plate Cover from ABgene
Polypropylene Plate Cover from ABgene
... polymer with a unique split septum design. Feat... tall-chimney plates (AB-0937, AB-1055, AB-1056) ...ew or clip-down hot lid thermal cyclers Pierceabl...ps may be pierced simultaneously Less than 0.5N ...
...native to traditional TBE (TRIS borate-EDTA) and T...onic Buffer allows for higher voltage runs, extrem...separation. -Application: Ready for use in gel ele...ations. Caution: Test electrophoresis chambers t...
Biology Products: